Tempus Wealth Planning LLC Increases Stock Position in Laboratory Co. of America Holdings (NYSE:LH)

Tempus Wealth Planning LLC boosted its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 9.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,180 shares of the medical research company’s stock after buying an additional 191 shares during the quarter. Tempus Wealth Planning LLC’s holdings in Laboratory Co. of America were worth $500,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. SouthState Corp bought a new position in Laboratory Co. of America during the third quarter worth about $28,000. Horizon Bancorp Inc. IN bought a new position in Laboratory Co. of America during the third quarter worth about $29,000. Fortitude Family Office LLC boosted its position in Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares during the period. Geneos Wealth Management Inc. boosted its position in Laboratory Co. of America by 309.8% during the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock worth $39,000 after purchasing an additional 127 shares during the period. Finally, Riverview Trust Co boosted its position in Laboratory Co. of America by 172.6% during the third quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock worth $38,000 after purchasing an additional 107 shares during the period. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Trading Down 0.5 %

Shares of LH opened at $246.70 on Wednesday. The firm’s 50 day simple moving average is $236.14 and its 200 day simple moving average is $228.95. The company has a market capitalization of $20.63 billion, a P/E ratio of 47.72, a P/E/G ratio of 1.86 and a beta of 1.07. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59.

Laboratory Co. of America Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.17%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Insiders Place Their Bets

In other news, CEO Adam H. Schechter sold 6,189 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $243.47, for a total value of $1,506,835.83. Following the transaction, the chief executive officer now owns 87,441 shares in the company, valued at approximately $21,289,260.27. This trade represents a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kerrii B. Anderson sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the transaction, the director now owns 12,722 shares in the company, valued at $2,989,670. This represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,572 shares of company stock valued at $5,915,209. 0.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on LH shares. Jefferies Financial Group reiterated a “buy” rating and set a $275.00 target price (up previously from $265.00) on shares of Laboratory Co. of America in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 30th. StockNews.com downgraded shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Friday, October 25th. UBS Group lowered their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Finally, Robert W. Baird increased their price target on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $263.46.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.